United States: Supreme Court To Decide Whether Supplying A Component From The US To A Manufacturing Facility Abroad Can Constitute Patent Infringement

On December 6, 2016, the Supreme Court heard oral argument in Life Tech. Corp. v. Promega Corp. addressing the circumstances under which a company may be subject to a finding of patent infringement of a US patent for shipping a component from the US to a manufacturing facility in a foreign country for assembly. This issue of infringement under 35 USC §271(f)(1) raises the question of when infringement of a US patent can result in damages for worldwide sales. This decision could impact any company that has components in its supply chain shipped from the US to its own manufacturing facility or to a contract manufacturer abroad.

Infringement under 35 USC § 271(f)(1)

35 USC §271(f)(1) was enacted by Congress in 1984 in response to the Supreme Court's decision in Deepsouth Packing Co. v. Laitram Corp., 406 US 518 (1972), which identified a perceived "loophole" in the US patent law.  Promega Corp. v. Life Tech. Corp., 773 F.3d 1338, 1352 (Fed. Cir. 2014). 

In Deepsouth, the Fifth Circuit affirmed an injunction after the defendant's shrimp deveining machine was found to infringe.  Id.  The defendant then began manufacturing certain components of its infringing shrimp deveining machine in the US and sending those parts abroad to its foreign customers for assembly of the infringing machines abroad.  Id.  The Supreme Court found that the sending of unassembled parts of the infringing machine to foreign customers did not infringe the US patent, which required the completed combination of those elements in the US. Id

In response to Deepsouth, Congress enacted 35 USC §271(f).  Id.  The portion of the statute before the Supreme Court today is 35 USC §271(f)(1), which states:

Whoever without authority supplies or causes to be supplied in or from the United States all or a substantial portion of the components of a patented invention, where such components are uncombined in whole or in part, in such manner as to actively induce the combination of such components outside of the United States in a manner that would infringe the patent if such combination occurred within the United States, shall be liable as an infringer.

As the Federal Circuit recently explained, the policy goal of §271(f)(1) is to prevent copiers from avoiding US patents by supplying components of a patented product in this country for assembly of the components in a completed product abroad.  Promega, 773 F.3d at 1352.

The Federal Circuit's decision in Promega Corp. v. Life Tech. Corp.

In the district court, Promega accused Life Technologies' genetic testing kits of patent infringement under 35 USC §271(f)(1).  The accused testing kits include various components, e.g., a primer mix, a PCR reaction mix, a buffer solution, control DNA, and a Taq polymerase enzyme.  Life Technologies manufactured the accused testing kits in the UK.  It acquired a component of the accused kits, the Taq polymerase enzyme, from a third party in the US and shipped that single component to its manufacturing facility in the UK for incorporation into the completed product.  Notably, the Taq polymerase enzyme component is a commoditized item that can be used for various purposes separate and apart from the Life Technologies genetic testing kits.

The jury returned a verdict of willful infringement under 35 USC §271(f)(1), finding that all of Life Technologies' worldwide sales were attributable to infringing acts in the US.  Promega, 773 F.3d at 1345.  The finding of infringement under §271(f)(1) implicated worldwide sales based on Life Technologies supplying the Taq polymerase enzyme from the US to its facility in the UK where the accused testing kits were assembled.  Id. at 1350-56.  Following the jury verdict, the district court granted Life Technologies' JMOL of non-infringement, finding that Promega failed to present sufficient evidence to sustain a jury verdict of infringement.  Id. at 1345.

On appeal, the Federal Circuit reversed the district court's grant of JMOL of non-infringement. It concluded that there was sufficient evidence to support a finding of infringement under 35 USC §271(f)(1).  Id. at 1358, 1358.  In reaching this decision, the Federal Circuit reasoned that the statutory language "substantial portion of the components of a patented invention" in 35 USC §271(f)(1) could be met by a shipping a single component from the US to Life Technologies' facility in the UK.  The court explained that "the ordinary meaning of 'substantial portion' suggests that a single important or essential component can be a 'substantial portion of the components' of a patented invention." Id. at 1353.  Despite being a single, commoditized component of the accused products, the Federal Circuit reasoned that the Taq polymerase enzyme was a "substantial portion of the components of the patent invention" because, "[w]ithout Taq polymerase, the genetic testing kit recited in the [] patent would be inoperable because no PCR could occur." Id. at 1356.

The Supreme Court oral argument about the scope of 35 USC § 271(f)(1) and its policy implications

There was much debate at oral argument in the Supreme Court this week about the statutory language "supplies or causes to be supplied in or from the United States all or a substantial portion of the components" in §271(f)(1).  Life Technologies, the accused infringer, took the position that "substantial portion" is quantitative and relates to the number of components.  It argued that "substantial portion" means "approximating or very close or tantamount to all" of the components of the accused product.  Under its interpretation, an infringer would need to supply all or very close to all of the components of a patented invention, and would not infringe by supplying a single component from within the US to its manufacturer outside of the country. Promega, on the other hand, argued that "substantial portion" has a qualitative meaning such that "substantial portion" can refer to an important portion of the patented invention even if that is a single, commoditized component.

During oral argument, the Supreme Court also discussed the policy implications surrounding the reach of US patent laws.  Both Justices Kennedy and Breyer questioned the economic impact of affirming the Federal Circuit's interpretation of 35 USC §271(f)(1) given the complex supply chains employed today.

JUSTICE KENNEDY: That -- that – that sounds to me much more like (f)(2) than (f)(1), but I'll -- I'll -- I'll look at that. The -- the -- the brief by Agilent Technologies was instructive for me as to how modern supply chains work. They say it's very complex. They ship out hundreds of different things. And that seems to me to give some help to the Petitioner, because it shows that a quantitative test is simply a good baseline to begin with, and the more egregious cases, it seems to me, are under (f)(2) anyway. If we have -- if we can think of horror stories, they are mostly covered by (f)(2), aren't they?

*  *  *  *

JUSTICE BREYER: That's US conduct, but you read the brief of the German companies, and they said it's a fairly common thing. We've been making product X forever, and now we invest in an American company, and lo and behold, we just want to import some wood. You know, just some wood, and -- and -- and we can't do it, because we'll be had up under this, because wood is an important -- some kind of -- is -- 30 percent of some kind of a patented thing that we've been making for years.

Further, counsel for Life Technologies argued that the Federal Circuit's interpretation would cause an explosion of NPE litigation against companies in the supply chain that would ultimately have a negative impact on the US economy.  Life Technologies argued as follows:

Justice Kennedy, you asked the question about, you know, what are we supposed to do in these circumstances as -- you know, with supply chains? And the answer is -- you know, the answer that my colleague gave you was one that basically says, this is a recipe for the trolls of the world to go and chase down every supply opportunity. And do what? Send them notice that what you're sending is a staple article that's a major component of a piece that's in the patent, and that if you send -- keep sending that, you're going to violate that patent and we're going to come after you. And what's that going to do? That's going to disrupt the supply chain in the United States, and the ultimate effect is going to be twofold: Either purchasers outside the US will stop purchasing from inside the US, or US manufacturers will go offshore. And the one thing we know that 271(f) was never intended to do was to accomplish that kind of an -- that kind of an impact -- negative impact on the US economy.

The oral argument thus addressed both the statutory interpretation issues and the possible real world effects of the Supreme Court's decision.


If the Supreme Court upholds the Federal Circuit's decision, 35 USC §271(f)(1) will be construed broadly such that providing even a single, significant component sourced from the US to a foreign manufacturing facility may expose a company to liability for patent infringement with damages encompassing both domestic and foreign manufacturing and sales.  On the other hand, if the Supreme Court overturns the Federal Circuit and more strictly construes 35 USC §271(f)(1), a company's exposure under this statute may be reduced.

Dentons is the world's first polycentric global law firm. A top 20 firm on the Acritas 2015 Global Elite Brand Index, the Firm is committed to challenging the status quo in delivering consistent and uncompromising quality and value in new and inventive ways. Driven to provide clients a competitive edge, and connected to the communities where its clients want to do business, Dentons knows that understanding local cultures is crucial to successfully completing a deal, resolving a dispute or solving a business challenge. Now the world's largest law firm, Dentons' global team builds agile, tailored solutions to meet the local, national and global needs of private and public clients of any size in more than 125 locations serving 50-plus countries. www.dentons.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
26 Sep 2018, Conference, New York, United States

Dentons is delighted to support a global IT services and consulting firm Miratech as an event host partner at their annual conference called M-Force18 New York on September 27th. The event will be held at Dentons New York office in the heart of Midtown Manhattan, opposite Rockefeller Center.

2 Oct 2018, Seminar, Dallas, United States

We are pleased to offer a program of five sessions designed specifically for in-house counsel. Topics will include:

  • In-house corporate ethical issues
  • What recent Supreme Court decisions mean for business
  • Keeping lawyers out of your benefit plans
  • Litigation tactics for in-house counsel
  • Employment issues in the age of #MeToo
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions